GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » 3-Year RORE %

IMTH (Innovative MedTech) 3-Year RORE % : -47.83% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Innovative MedTech's 3-Year RORE % for the quarter that ended in Sep. 2024 was -47.83%.

The industry rank for Innovative MedTech's 3-Year RORE % or its related term are showing as below:

IMTH's 3-Year RORE % is ranked worse than
80.22% of 804 companies
in the Medical Devices & Instruments industry
Industry Median: -8.405 vs IMTH: -47.83

Innovative MedTech 3-Year RORE % Historical Data

The historical data trend for Innovative MedTech's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative MedTech 3-Year RORE % Chart

Innovative MedTech Annual Data
Trend Oct10 Oct11 Oct12 Oct13 Oct14 Jun20 Jun21 Jun22 Jun23 Jun24
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -85.19 -47.50

Innovative MedTech Quarterly Data
Jul14 Oct14 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.46 -84.02 -15.06 -47.50 -47.83

Competitive Comparison of Innovative MedTech's 3-Year RORE %

For the Medical Instruments & Supplies subindustry, Innovative MedTech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative MedTech's 3-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's 3-Year RORE % falls into.



Innovative MedTech 3-Year RORE % Calculation

Innovative MedTech's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.35--1.12 )/( -1.61-0 )
=0.77/-1.61
=-47.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


Innovative MedTech  (OTCPK:IMTH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Innovative MedTech 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative MedTech Business Description

Traded in Other Exchanges
N/A
Address
2310 York Street, Suite 200, Blue Island, IL, USA, 60406
Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: technology and devices and Adult Day Services.
Executives
Merle Griff officer: Chief Executive Officer 2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner 10 percent owner 70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt director, 10 percent owner, other: Chairman of the Board 2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman 10 percent owner 280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts 10 percent owner 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman director, 10 percent owner, officer: President & CEO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc. 10 percent owner 881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine director, officer: CFO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari director, officer: COO 280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz director 280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo director, officer: President 3163 KENNEDY BLVD, JERSEY CITY NJ 07306